PharVision Advisers’s Ardent Health ARDT Stock Holding History

PharVision Advisers’s Portfolio ARDT Stock Details ARDT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-13,642	Closed	-$188K	–	455
2025 Q1	$188K	Buy	+13,642	New	+$199K	0.26%	205

Other funds holding ARDT

CTC

Chai Trust Company Chicago, Illinois $1.18B AUM 19.62% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CastleKnight Management New York $6B AUM 121.87% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GAM

Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

PharVision Advisers's ARDT Position: Q2 2025 in Review

PharVision Advisers sold out of Ardent Health (ARDT) in Q2 2025, closing a stake of 13,642 shares — an estimated $188K sold.

PharVision Advisers first reported a position in ARDT in Q1 2025 and held it in 1 quarter. The position peaked at $188K in Q1 2025. 110 funds tracked by Wall St. Rank hold ARDT as of Q2 2025.

PharVision Advisers reported no remaining Ardent Health position as of Q2 2025 after selling out during the quarter.
PharVision Advisers sold 13,642 Ardent Health shares in Q2 2025, an estimated $188K.
PharVision Advisers first reported a position in Ardent Health in Q1 2025 and held it in 1 quarter.
PharVision Advisers's Ardent Health position peaked at $188K in Q1 2025.
110 funds tracked by Wall St. Rank held Ardent Health as of Q2 2025.

Based on PharVision Advisers's 13F filing for Q2 2025, filed 13 Aug 2025.